Literature DB >> 3156088

Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma.

R J North, E S Dye.   

Abstract

It has been shown that progressive growth of the P815 mastocytoma in its semisyngeneic B6D2 host results, between days 6 and 9 of tumour growth, in the generation of Ly 1-2+ T cells which are capable, on passive transfer, of causing the regression of an established tumour in gamma-irradiated recipients, and of T cells which are capable of lysing P815 tumour cells in vitro. After 9 days of tumour growth, these effector T cells are progressively lost; this is associated with the progressive acquisition of Ly 1+2- suppressor T cells which are capable of inhibiting the expression of passively transferred immunity against an established tumour in T-cell deficient recipients. The results are consistent with the hypothesis that this P815 mastocytoma grows progressively, in spite of its immunogenicity, because it evokes the generation of suppressor T cells before enough effector T cells are generated to reject it.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156088      PMCID: PMC1454849     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

Review 1.  Suppressor cells: permitters and promoters of malignancy?

Authors:  D Naor
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

2.  Immunoregulatory circuits among T cell sets: effect of mode of immunization on determining which Lyl T cell sets will be activated.

Authors:  D D Eardley; J Kemp; F W Shen; H Cantor; R K Gershon
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

3.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

Authors:  K T Brunner; J Mauel; J C Cerottini; B Chapuis
Journal:  Immunology       Date:  1968-02       Impact factor: 7.397

Review 4.  Concomitant tumor immunity and the resistance to a second tumor challenge.

Authors:  E Gorelik
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

5.  Suppressor T cell circuits.

Authors:  B Benacerraf; M I Greene; M S Sy; M E Dorf
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

6.  Suppressor cells in tumor-bearing mice capable of nonspecific blocking of in vitro immunization against transplant antigens.

Authors:  A E Eggers; J R Wunderlich
Journal:  J Immunol       Date:  1975-05       Impact factor: 5.422

7.  In vivo and in vitro antitumor activity expressed by cells of concomitantly immune mice.

Authors:  R L Tuttle; V C Knick; C R Stopford; G Wolberg
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

8.  T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

Authors:  E S Dye; R J North
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

9.  Suppressor T cells activated in a primary in vitro response to non-major histocompatibility alloantigens.

Authors:  S Macphail; O Stutman
Journal:  J Exp Med       Date:  1982-11-01       Impact factor: 14.307

10.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  14 in total

1.  Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.

Authors:  A L Rakhmilevich; J Turner; M J Ford; D McCabe; W H Sun; P M Sondel; K Grota; N S Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation.

Authors:  A M Claessen; H Valster; H Bril; S Meyer; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Sublethal, whole-body ionizing irradiation can be tumor promotive or tumor destructive depending on the stage of development of underlying antitumor immunity.

Authors:  M Awwad; R J North
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 5.  CD25+ CD4+ regulatory T-cells in cancer.

Authors:  David C Linehan; Peter S Goedegebuure
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

6.  Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.

Authors:  T H Inge; S K Hoover; J L Frank; T T Kawabata; K P Bethke; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

7.  Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity.

Authors:  R J North; R H Neubauer; J J Huang; R C Newton; S E Loveless
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

8.  In vitro expression of secondary antitumor immunity by in vitro tumor-sensitized T cells: inhibition by tumor-induced suppressor T cells.

Authors:  Z Kaymakcalan; G L Spitalny; I Bursuker
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity.

Authors:  M Awwad; R J North
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

10.  T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity.

Authors:  A DiGiacomo; R J North
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.